Supporters
Partners
Gastrointestinal Cancer
Gastrointestinal cancer refers to cancer which forms within the gastrointestinal tract, somewhere in the esophagus, stomach, liver, biliary system, pancreas, bowels, or anus. Several risk factors for developing gastrointestinal cancer have been identified. The frequency of gastrointestinal tumors increases with each decade of life and these tumors occur somewhat more frequently in men than in women. Persons of Asian, Pacific Islander, Hispanic and African American descent have a statistically higher chance of developing the cancer compared to non-Hispanic white Americans. Additionally, eating smoked, salted or pickled foods may lead to an increased risk, whereas eating fresh fruits and vegetables lowers the risk. Also, as with several other cancers, cigarette smokers tend to have increased rates of stomach cancers.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin | III | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Xeloda and Cisplatin (First Line Therapy) | III | Gastrointestinal (Stomach) Cancer |
| Amgen Inc | AMG102 with Epirubicin, Cisplatin and Capecitabine (First Line Therapy) | II | Gastrointestinal (Stomach) Cancer |
| Amgen Inc | AMG386 | II | Gastrointestinal (Stomach) Cancer |
| Amgen Inc | AMG706 | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Capecitabine and Carboplatin | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Capecitabine, Oxaliplatin and Radiation Therapy | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Docetaxel, Cisplatin and Irinotecan | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with FOLFOX | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Taxotere | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Avastin with Xelox | II | Gastrointestinal (Stomach) Cancer |
| ACT Biotech, Inc. | BAY579352 (First Line) | II | Gastrointestinal (Stomach) Cancer |
| ACT Biotech, Inc. | BAY579352 (Second Line) | II | Gastrointestinal (Stomach) Cancer |
| Regulon, Inc | Lipoplatin with Radiotherapy, 5-Fluorouracil | II | Gastrointestinal (Stomach) Cancer |
| Regulon, Inc | Lipoxal | II | Gastrointestinal (Stomach) Cancer |
| Onyx Pharmaceuticals Inc | Nexavar | II | Gastrointestinal (Stomach) Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Docetaxel and Cisplatin | II | Gastrointestinal (Stomach) Cancer |
| SuperGen Inc | Orathecin | II | Gastrointestinal (Stomach) Cancer |
| HERMES Biosciences | PEP02 | II | Gastrointestinal (Stomach) Cancer |
| Genentech, Inc. | Tarceva with FOLFOX6 | II | Gastrointestinal (Stomach) Cancer |
| Exelixis Inc | XL880 | II | Gastrointestinal (Stomach) Cancer |
Head and Neck Cancer
Most head and neck cancers begin in the mucous linings in the head and neck, such as the sinuses, mouth and larynx. Symptoms of such a cancer usually include a lump or sore that does not heal, a persistent sore throat, difficulty swallowing and a change of hoarseness in the voice. As many as 90 percent of head and neck cancers arise after prolonged exposure to specific factors including tobacco (cigarettes, cigars, chewing tobacco or snuff) and/or alcoholic beverages. Prolonged exposure to sunlight is linked with cancer of the lip and is also a major cause of skin cancer. There were about 40,490 new cases in 2006.
| Company | Product | Phase | |
| Genentech, Inc. | Avastin | III | Head and Neck Cancer |
| Regulon, Inc | Lipoplatin with fluorouracil | III | Head and Neck Cancer |
| Genentech, Inc. | Tarceva | III | Head and Neck Cancer |
| Amgen Inc | Vectibix | III | Head and Neck Cancer |
| Abraxis BioScience, Inc. | Abraxane with Carboplatin, Erbitux and IMRT | II | Head and Neck Cancer |
| Genentech, Inc. | Alimta with Avastin | II | Head and Neck Cancer |
| Genentech, Inc. | Avastin with Tarceva | II | Head and Neck Cancer |
| Genentech, Inc. | Avastin with Tarceva and Radiation | II | Head and Neck Cancer |
| Genentech, Inc. | Avastin with Tarceva, Chemotherapy and Radiation Therapy | II | Head and Neck Cancer |
| Regulon, Inc | Lipoplatin with Radiation | II | Head and Neck Cancer |
| Onyx Pharmaceuticals Inc | Nexavar with Carboplatin and Paclitaxel | II | Head and Neck Cancer |
| Cytokinetics Inc | SB715992 (First or Second Line Therapy) | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva with Bevacizumab or Sulindac | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva with Docetaxel and Cisplatin | II | Head and Neck Cancer |
| Genentech, Inc. | Tarceva with RADPLAT | II | Head and Neck Cancer |
| Exelixis Inc | XL880 | II | Head and Neck Cancer |
